NeuroInsights and BioToday Launch Neurotechnology Investment Newsletter in Japan
News and Analysis Helps Japanese Investors, Companies, and Researchers Profit from Advances in the Brain Industry
SAN FRANCISCO – October 31, 2005 –NeuroInsights, the neurotechnology market authority, announced today that it is working with Japan’s BioToday.com, to launch Neurotech Insights, the neurotechnology investment newsletter, in Japanese. Neurotechnology is a highly active and profitable industry, including pharmaceuticals, devices, and diagnostics, with global revenues of almost $100 billion in 2004.
Neurotech Insights provides in depth feature articles, private company news, product development tracking, executive interviews, and public stock commentary based on a deep and intimate understanding of the industry players and products. This month’s issue, focused on the obesity market, details basic research, clinical trial pipelines, gastric neurostimulation devices, and includes an interview with Arena Pharmaceutical’s CEO, Jack Lief. Previous issues have focused on stem cells, stroke, pain, and schizophrenia. Future issues will discuss Alzheimer’s disease, epilepsy, and nutriceuticals for improved cognition.
“NeuroInsights is pleased to be working with BioToday to translate and distribute Neurotech Insights, the neurotechnology industry’s leading global investment newsletter to Japanese executives and investors” said Zack Lynch, publisher of Neurotech Insights. “Japanese researchers and companies are on the cutting edge of neurotechnology research and development and this should provide them with improved global visibility to compete more effectively now and in the future.”
“Neurotech Insights is the world’s first information source to bridge basic information for CNS diseases, products and market opportunities, that is unprecedented in commercially available reports,” said Seimiya Masato, President of BioToday. “Neurotech Insights provides in depth insights about neurotech markets which accelerates communication and discovery among business and scientific leaders, strengthening worldwide competitiveness of Japanese researchers and companies.“
Neurotechnology companies represent exceptional opportunities for knowledgeable investors to profit from advances in treatments for the brain and nervous system. NeuroInsights’ Neurotech Index, an equal-dollar weighted tracking index of 30 neurotechnology companies, is up 31% over a one year period, compared to a 7% gain in both the S&P 500 Index and the NASDAQ Composite. Information about the index is featured each month in Neurotech Insights.
About NeuroInsights
As the neurotechnology market authority, NeuroInsights™ helps investors, industry executives and the public understand and profit from the rapid growth of companies treating brain and nervous system-related illnesses, providing:
· Industry reports and publications;
· Custom economic development analysis;
· Strategic advisory services;
· Events and conferences;
· Market news and investment newsletters.